Online inquiry

IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15903MR)

This product GTTS-WQ15903MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15903MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15297MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ6907MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ4738MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ5121MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ13032MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ12839MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ13648MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ6094MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW